Haematuria in Postrenal Transplant Patients

Table 1

Patient demographics and treatment regime of renal transplant patients who developed bladder carcinoma.

Comparison	Rogers et al., BJUI, UK, 2012 [71]	Prabharasuth et al., J Urol, USA, 2013 [72]	Moses et al., Transplant Proc, USA, 2013 [73]	Master et al., J Urol, USA, 2004 [24]	Manassero et al., Transplant International, Italy, 2011 [74]	Kamal et al., BJU, Egypt, 2008 [35]	Tomaszewski, AIU, USA, 2011 [36]	Lang et al., J Urol, Germany, 2005 [75]
	8	17	5	5	4	7	7	4
Stage	pTa-T2	pTa-T3	pT0-T3	pT1-T3a	pT1-T3a	pTis-T3a	pTis-T3a	pTa-T3b
Mean time to development of TCC after transplant (months)	60	88.1	83.9	106.8	102	112.8	39	126
Treatment	TURBT (), RCIUD ()	RCIUD (), RCNB () TURBT (), Chemo (), palliative RT ()	RCNB ()	TURBT (), RCIUD (), RCNB ()	RCNB ()	RCNB (), TURBT ()	Palliative RT + IUD (), palliative RT (), RCIUD (), TURBT ()	RCNB ()
Mean follow-up (months)	144	9.2	24.9	33.6	31.5	10.3	36.3	52
Recurrence rate	2/8	8/16 (1 palliative RT)	2/5	—	2/4	3/7	2/5 (2 palliative RT)	1/4

TURBT: transurethral resection of bladder tumour; RC: radical cystectomy; IUD: incontinent urinary diversion; NB: neobladder.